Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
GLOBETECH PUBLISHING LLC
Ampronix

PET-CT Identifies Ruptured and High-Risk Coronary Plaque

By Medimaging International staff writers
Posted on 09 Jan 2014
Image: The Biograph mCT PET-CT system by Siemens Healthcare (Photo courtesy of Siemens Healthcare).
Image: The Biograph mCT PET-CT system by Siemens Healthcare (Photo courtesy of Siemens Healthcare).
Scientists have discovered that the tracer 18F-sodium fluoride (18F-NaF) used with positron emission tomography-computed tomography (PET-CT) imaging technology is the first noninvasive imaging modality to identify and localize ruptured and high-risk coronary plaque.

The University of Edinburgh (Scotland, UK) is leading the heart disease study with the help of a Biograph mCT PET-CT system developed by Siemens Healthcare (Erlangen, Germany). The new study’s findings were published October 2013 in the Lancet. Currently there is no noninvasive way of finding high-risk plaques at risk of rupturing and causing a heart attack. The imaging technology is providing new clues into clinical research into early diagnosis of the disorder.

In the prospective clinical trial, patients with myocardial infarction and stable angina underwent 18F-NaF and 18F-fluorodeoxyglucose (18F-FDG) PET-CT and invasive coronary angiography. 18F-NaF uptake was compared with histology in carotid endarterectomy specimens from patients with symptomatic carotid disease, and with intravascular ultrasound in patients with stable angina. The primary endpoint was the comparison of 18F-fluoride tissue-to-background ratios of culprit and non-culprit coronary plaques of patients with acute myocardial infarction.

In 93% (37) of patients with myocardial infarction, the highest coronary 18F-NaF uptake was seen in the culprit plaque. By contrast, coronary 18F-fluorodeoxyglucose (FDG) uptake was typically concealed by myocardial uptake and where discernible, there were no differences between culprit and non-culprit plaques. Marked 18F-NaF uptake occurred at the site of all carotid plaque ruptures and was linked with histologic evidence of active calcification, macrophage infiltration, apoptosis, and necrosis. Forty-five percent (18) of patients with stable angina had plaques with focal 18F-NaF uptake that were associated with more high-risk features on intravascular ultrasound than those without uptake.

The plaque areas in the blood vessels were easily identifiable by using the Biograph mCT scanner. In the patients with angina, advanced notice that they had high-risk plaques and a heart attack may be impending. These patients could then be targeted with aggressive therapy to avoid future events.

“Being able to identify dangerous fatty plaques likely to cause a heart attack is something that conventional heart tests can’t do. This research suggests that PET-CT scanning may provide an answer, identifying ‘ticking time bomb’ patients at risk of a heart attack,” said Prof. Peter Weissberg, medical director at the British Heart Foundation (BHF; London, UK). “Nearly 20 years of BHF-funded research has led us to this point. We now need to confirm these findings, and then understand how best to use new tests like this in the clinic to benefit heart patients.”

BHF clinical lecturer and cardiologist Dr. Marc Dweck, who led the research at the University of Edinburgh, stated: “We have developed what we hope is a way to ‘light up’ plaques on the brink of rupturing and causing a heart attack. If we could know how close a person is to having a heart attack, we could step in with medication or surgery before the damage is done. This is a first step towards that goal. The next stage is to confirm these findings in larger studies to establish first that this technique can truly predict heart attacks and secondly that treatment can help patients avoid these events.”

“Siemens Healthcare is delighted that the Biograph mCT is aiding ground-breaking research into the UK’s biggest killer—heart disease,” remarked Lawrence Foulsham, business manager, molecular imaging at Siemens Healthcare. “The condition is a clinical priority for the UK; therefore advancements in this field are incredibly important. We have a long-standing partnership with the Clinical Research Imaging Center at the University of Edinburgh and look forward to assisting them with further clinical research insights into the future.”

The Clinical Research Imaging Center at the University of Edinburgh installed the Biograph mCT in 2010.

Related Links:

Siemens Healthcare
University of Edinburgh



Channels

MRI

view channel

Alzheimer’s Disease Linked to Specific Lifestyle Risk Factors

The results of a new study have found that cardiovascular risk factors such as smoking, alcohol consumption, diabetes, and obesity, can be linked directly to smaller brain volumes in specific areas of the brain, and to lower cognitive test scores. The study was published online in the Radiological Society of North America... Read more

Ultrasound

view channel

New Ultrasound System Enhances Patient Care and User Experience

A new ultrasound system with innovative specialized transducers and improved image quality, intended for general imaging, women’s health, and shared service applications, has been announced. The system features improved accuracy, performance, assessment tools, advanced automation, and an enhanced user experience.... Read more

Nuclear medicine

view channel

Clinical Study Shows Added Value of Amyloid PET Imaging in the Diagnosis and Treatment of Dementia

Early-onset dementia patients could benefit from a new PET imaging agent developed by a major medical imaging vendor. The results of a clinical study showing the effectiveness of the amyloid PET imaging agent were presented at the Alzheimer’s Association International Conference (AAIC 2015) in Washington DC (USA).... Read more

General/Advanced Imaging

view channel
Image: Illustration of a new technique using Optical Coherence Tomography that could help surgeons differentiate a human brain tumor, red, from surrounding noncancerous tissue, green (Photo courtesy of  Carmen Kut, Jordina Rincon-Torroella, Xingde Li and Alfredo Quinones-Hinojosa/Johns Hopkins Medicine).

Imaging Technique Helps Safer and More Effective Removal of Brain Tumors

Researchers at the Johns Hopkins University have demonstrated a new imaging technology that could enable neurosurgeons to better differentiate between healthy and cancerous brain tissue and perform safer... Read more

Imaging IT

view channel
Image: The Arbor Solution M2150 medical workstation with 21.5\

Multifunction Workstation Screen Meets Critical Certification Standards for Medical Environments

A medical imaging equipment vendor has unveiled a new workstation with a 54.61 cm true flat screen designed for operating rooms, clinical stations, and Picture Archiving and Communications Systems (PACS).... Read more

Industry News

view channel

Guerbet Aims for Global Medical Imaging Leadership by Acquisition of Mallinckrodt’s CMDS Business

Guerbet (Paris, France) has announced a definitive agreement for the acquisition of the Contrast Media and Delivery Systems (CMDS) business of pharmaceutical giant Mallinckrodt (Chesterfield, Derbyshire, UK). The acquisition gave Guerbet and the CMDS unit combined pro-forma sales of nearly EUR 800 million in 2014, a... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.